hTNFR2

通过同源重组，将小鼠Tnfrsf1b基因进行人源化修饰。

Fig.1 Detection of TNFRSF1B expression by RT-PCR. 

Wild type: only one band at 247 bp with primers F2/R2(mTnfrsf1b);

Homozygous: only one band at 255 bp with primers F1/R1(hTNFRSF1B); 

Abbr.. M, DNA marker; HO, homozygous; HE, heterozygous; WT, wild type.

Fig.2 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in spleen in HE hTNFR2 mice.（In collaboration with CrownBio）

Fig.3 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in Peripheral Blood in HE hTNFR2 mice.（In collaboration with CrownBio）

Fig.4 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in Lymph node in HE hTNFR2 mice.（In collaboration with CrownBio）

Fig.5 Detection of human/mouse TNFRSF1B(TNFR2) expression on T cells in spleen in HO hTNFR2 mice.（In collaboration with CrownBio）

Fig.6 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in spleen in HO hTNFR2 mice.（In collaboration with CrownBio）

Fig.7 In vivo efficacy evaluation of anti-hTNFR2 in TNFR2 HuGEMM mice with MC38-OVA tumors.（In collaboration with CrownBio）

Homozygous humanized TNFRSF1B mice were inoculated with MC38 colon cancer cells. The drug targeting human TNFRSF1B, showed a very significant anti-tumor effect, demonstrating that the humanized TNFRSF1B mice are a good in vivo model for validating the efficacy of antibodies targeting human TNFRSF1B.

Fig.8 FACS for blood upon TNFR2 antagonist treatment.（In collaboration with CrownBio）

Addition of antagonistic hTNFRSF1B antibody can impair hTNF-induced Treg cells proliferation, while the agonistic hTNFRSF1B antibody alone can induce a modest proliferative response.

Fig.9 TIL analysis upon TNFR2 antagonist treatment.（In collaboration with CrownBio）

1 tumor in hTNFR2 Ab1 treatment group decreased  (1/7, TV=0)

2 tumors in hTNFR2 Ab2 treatment group decreased  (2/7, TV=0; 3/7 died during dosing period)

Fig.10 TNFRSF1B blockade increases the Teff/Treg ratios in tumor microenvironment. （In collaboration with CrownBio）